Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 32Tumor-Agnostic 1Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 78Fulvestrant 76Carboplatin 74Trastuzumab 71Capecitabine 70Letrozole 63Cyclophosphamide 61Paclitaxel 60Specimen Handling 54pertuzumab 52Docetaxel 50abemaciclib 46ribociclib 45Anastrozole 36Magnetic Resonance Spectroscopy 35130-nm albumin-bound paclitaxel 35trastuzumab deruxtecan 34Blood Specimen Collection 33exemestane 32Tamoxifen 32Biopsy 32sacituzumab govitecan 31Gemcitabine 30Epirubicin 29pyrotinib 28palbociclib 28Drug Therapy 28Surveys and Questionnaires 27Injections 27eribulin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × enfortumab vedotin × Breast × Clear all
NCT07287995 2026-04-23

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Astellas Pharma Inc

Phase 1/2 Recruiting
428 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡